Stock Analysis

Prenetics Global Full Year 2022 Earnings: Misses Expectations

Source: Shutterstock

Prenetics Global (NASDAQ:PRE) Full Year 2022 Results

Key Financial Results

  • Revenue: US$275.8m (flat on FY 2021).
  • Net loss: US$190.5m (loss widened by 9.5% from FY 2021).
  • US$2.51 loss per share.
NasdaqGM:PRE Earnings and Revenue Growth March 16th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Prenetics Global Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 4.2%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 8.6% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Prenetics Global that you should be aware of.

What are the risks and opportunities for Prenetics Global?

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company.

View Full Analysis


  • Earnings are forecast to grow 122.16% per year


  • Volatile share price over the past 3 months

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report